Genetic variation in CHRNA5, the gene encoding the a5 nicotinic acetylcholine receptor subunit, increases vulnerability to tobacco addiction and lung cancer, but the underlying mechanisms are unknown. Here we report markedly increased nicotine intake in mice with a null mutation in Chrna5. This effect was 'rescued' in knockout mice by re-expressing a5 subunits in the medial habenula (MHb), and recapitulated in rats through a5 subunit knockdown in MHb. Remarkably, a5 subunit knockdown in MHb did not alter the rewarding effects of nicotine but abolished the inhibitory effects of higher nicotine doses on brain reward systems. The MHb extends projections almost exclusively to the interpeduncular nucleus (IPN). We found diminished IPN activation in response to nicotine in a5 knockout mice. Further, disruption of IPN signalling increased nicotine intake in rats. Our findings indicate that nicotine activates the habenulo-interpeduncular pathway through a5-containing nAChRs, triggering an inhibitory motivational signal that acts to limit nicotine intake.
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Tobacco smoking results in more than 5 million deaths each year and accounts for almost 90% of all deaths from lung cancer 1 . Nicotine is the principal reinforcing component in tobacco smoke responsible for addiction 2 . Nicotine acts in the brain through neuronal nicotinic acetylcholine receptors (nAChRs), which are ligand-gated ion channels consisting of five membrane-spanning subunits 3 . Twelve neuronal nAChR subunits have been identified: nine a subunits (a2-a10) and three b subunits (b2-b4) 3 . The predominant nAChR subtypes in mammalian brain that have been heavily implicated in regulating the addictive properties of nicotine are those containing a4 and b2 subunits [4] [5] [6] [7] [8] . A major advance in our understanding of smoking behaviour is the finding that allelic variation in the a5/a3/b4 nAChR subunit gene cluster located in chromosome region 15q25 significantly increases risk of tobacco addiction [9] [10] [11] . In particular, polymorphisms in the a5 subunit gene (CHRNA5), which result in decreased function of the subunit, increase vulnerability to tobacco addiction 12, 13 . Nevertheless, mechanisms through which nAChRs that contain the a5 subunit (denoted as a5* nAChRs) may influence smoking behaviour are unclear. Genetic variability in CHRNA5 is also a major risk factor for lung cancer and chronic obstructive pulmonary disease (COPD) in smokers [14] [15] [16] , which may reflect higher levels of tobacco dependence in individuals carrying risk alleles and consequently greater exposure to carcinogens contained in tobacco smoke 17 , although the precise role of a5* nAChRs in lung cancer and COPD is unknown.
a5* nAChRs control nicotine intake
Here we investigated the role of a5* nAChRs in the reinforcing properties of nicotine. We found that wild-type mice and mice with a null mutation in a5 subunits, which therefore did not express a5* nAChRs, responded for intravenously self-administered nicotine infusions according to an inverted U-shaped dose-response curve, consistent with previous reports in humans 18 , non-human primates 19 , dogs 20 and rats 21 . However, the knockout mice responded far more vigorously than wild-type mice for nicotine infusions, especially when higher unit doses were available (Fig. 1a) . Increased responding for nicotine in knockout mice was not secondary to alterations in operant performance or the motivational salience of reward-paired conditioned stimuli ( Supplementary Fig. 1 ). When we calculated the total amount of nicotine consumed at each dose available for self-administration, we found that wild-type mice titrated their responding to consume ,1.5 mg kg 21 per session (Fig. 1b) ; which achieves plasma concentrations of nicotine comparable to those detected in humans after 5 h of smoking their preferred brand of cigarette 23, 24 . In contrast, knockout mice did not titrate their responding and consumed greater amounts of nicotine as the dose increased (Fig. 1b) . Knockout mice also had greater motivation to seek and obtain nicotine when tested under a progressive ratio schedule of reinforcement, an effect most apparent again at high doses ( Supplementary Fig. 2 ). Enhanced responding for nicotine as the unit dose increases is thought to reflect an intensification of the reinforcing properties of the drug, thereby motivating higher levels of intake 25 . Diminished responding as the dose increases reflects greater restraint over intake to avoid the increasingly aversive effects of higher drug doses 18, 25 or more rapid development of drug satiation 25, 26 . Our findings indicate, therefore, that deletion of a5* nAChRs has a dissociable effect on the motivational drives that control nicotine intake. The stimulatory effects of nicotine on brain reinforcement systems (ascending portion of dose-response curve) are unaltered by a5 subunit knockout, as the wild-type and knockout mice responded for nicotine at a similar maximal rate. Instead, deficient a5* nAChR signalling seems to attenuate the negative effects of nicotine that limit its intake (descending portion of dose-response curve); see also ref. 22 . These findings are highly consistent with the increased vulnerability to tobacco addiction in human smokers carrying CHRNA5 risk alleles that result in less functional a5* nAChRs 12, 13 .
Habenular a5* nAChRs control nicotine intake
The a5 nAChR subunit has a restricted distribution profile in the brain, with dense expression in the habenulo-interpeduncular pathway, deep layers of the cortex and hippocampus, and lower expression in the ventral tegmental area (VTA) and substantia nigra 27 . The MHb projects almost exclusively to the IPN via the fasciculus retroflexus 28 . Functional a5* nAChRs are expressed on MHb afferents to the IPN 29 , and high but not low nicotine doses activate the habenulointerpeduncular tract, as measured by increased local glucose utilization in rats 30 . The habenulo-interpeduncular tract regulates avoidance of noxious substances 31 and regulates somatic aspects of nicotine withdrawal 32 . However, little is known of its role in drug-taking behaviour 33 . Intriguingly, the lateral habenula (LHb) has an inhibitory influence on VTA dopamine neurons 34 , is activated by aversive stimuli or omission of anticipated reward, and is considered to be a source of negative motivational signals in the brain 34 . We proposed therefore that nicotine-induced stimulation of a5* nAChRs in the habenulo-interpeduncular pathway triggers an inhibitory motivational signal that limits consumption of the drug. In knockout and wild-type mice that received injections of a control lentivirus expressing green-fluorescent protein (GFP; Lenti-Control) into the MHb, we again found that knockout mice self-administered far greater amounts of nicotine when a high unit dose was available (Fig. 2a) , replicating the earlier findings. However, nicotine intake was indistinguishable in knockout versus wild-type mice after injection of a lentivirus vector (Lenti-CHRNA5) into the MHb to rescue a5* nAChR in the habenulointerpeduncular tract ( Fig. 2b and Supplementary Fig. 3 ). GFP immunostaining to confirm MHb delivery of virus was carried out for the majority of the mice. Responding for nicotine (0, 0.1 and 0.4 mg kg 21 per infusion) in the subset of Lenti-CHRNA5-treated mice used for immunostaining was 3.6 6 0.83, 8.8 6 1.4 and 4.86 6 1.0, respectively, for wild types and 4.53 6 0.85, 7.72 6 0.68 and 4.53 6 1.4, respectively, for knockouts. GFP immunostaining confirmed that virus-infected cells were detected almost exclusively in the habenulo-interpeduncular tract of Lenti-CHRNA5 knockout mice, with little detectable staining in other brain areas that could potentially affect self-administration behaviour (Fig. 2c, d , e and Supplementary Fig. 4 ). The remaining mice not used for immunostaining were used to verify that the Lenti-CHRNA5 virus was effective at 'rescuing' a5 subunit expression in the knockout mice. Real-time polymerase chain reaction (PCR) verified that a5 subunit mRNA was detectable only in the MHb (Supplementary Fig. 5 ) and IPN ( Supplementary Fig. 6 ) of the Lenti-CHRNA5-treated knockout mice, indicating that a5 subunit mRNA is transported from the MHb along the fasciculus retroflexus and into the IPN. Wild-type mice treated with the Lenti-CHRNA5 vector did not demonstrate increased a5 subunit mRNA above baseline levels in the MHb ( Supplementary  Fig. 5 ), indicating that strict regulatory mechanisms control a5 subunit expression levels in the habenulo-interpeduncular pathway.
Using radiolabelled rubidium ( 
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and IPN, but not the cortex or hippocampus, of a separate cohort of knockout versus wild-type mice ( Supplementary Fig. 7 ). Consistent with a recent report, 86 Rb 1 efflux was also attenuated in synaptosomes from the thalamus of knockout mice 35 ( Supplementary Fig. 7 ). Injections of Lenti-CHRNA5 into the MHb attenuated the deficits in 86 
Rb
1 efflux in the IPN, but not in the MHb or thalamus, of knockout mice ( Supplementary Fig. 8 ). These findings demonstrate that a5* nAChRs have a critical role in regulating nAChR transmission in the habenulo-interpeduncular tract, and confirm that the Lenti-CHRNA5 vector rescues not only expression, but also function, of a5* nAChRs in the habenulo-interpeduncular pathway. These data also reveal three additional insights. First, a5 subunits produced in MHb are predominately incorporated into a5* nAChRs expressed presynaptically on afferents to the IPN. Second, injection of the Lenti-CHRNA5 vector into MHb rescued local a5 subunit mRNA expression, but not deficits in MHb 86 
1 efflux. This indicates that nAChR signalling in the MHb may be derived from a5* nAChRs located presynaptically on afferent inputs from brain sites not infected by the virus. Third, although the Lenti-CHRNA5 vector attenuated the deficits in nAChR signalling detected in the IPN of knockout mice, this rescue was only partial (Supplementary Fig. 8 ). Hence, postsynaptically localized a5* nAChRs on IPN neurons, or perhaps presynaptic a5* nAChRs on afferent inputs that originate from brain sites other than the MHb, also have a major role in nAChR transmission in the IPN.
Next, we developed and validated a lentivirus vector to deliver a short hairpin RNA against the a5 nAChR subunit (Lenti-a5-shRNA; Supplementary Fig. 9 ). Then we microinjected the Lenti-a5-shRNA vector into the MHb of rats to knockdown habenulo-interpeduncular a5* nAChRs ( Supplementary Fig. 10 ). As expected, Lenti-Control rats responded for nicotine according to an inverted U-shaped doseresponse curve (Fig. 3a) . There was a marked increase in nicotine consumption across the dose-response curve in the Lenti-a5-shRNA rats that was most apparent at high unit doses (Fig. 3a) . When total nicotine intake at each dose was calculated, we found that LentiControl rats titrated their responding to consume ,0.75-1 mg kg 21 nicotine per session ( Supplementary Fig. 10 ). In contrast, the knockdown rats showed little evidence of titration and continued to increase their consumption as the unit dose increased. We obtained similar effects on nicotine intake using a second lentivirus vector that expressed an shRNA targeting a different portion of a5 subunit mRNA (Supplementary Fig. 11 ). Overall, these findings in rats recapitulate those in the a5 knockout mice and confirm that a5* nAChRs in the habenulo-interpeduncular pathway regulate levels of nicotine intake across species.
a5* nAChRs inhibit brain reward function
Next we examined the effects of nicotine on brain-stimulation reward (BSR) thresholds in rats after knockdown of a5* nAChRs in the habenulo-interpeduncular pathway. In the BSR procedure, rats respond vigorously to obtain rewarding electrical self-stimulation via an intracranial stimulating electrode, with the minimal stimulation intensity that maintains self-stimulation behaviour termed the reward threshold. Low doses of nicotine (,0.25 mg kg 21 ) that condition a place preference in rats also lower BSR thresholds 36 , reflecting drug-induced enhancement of brain reward activity. Conversely, higher doses of nicotine ($1 mg kg 21 ) that condition a place aversion can raise the BSR thresholds in rats 37 . Importantly, rats regulate their pattern of nicotine self-administration behaviour at a level that achieves maximal lowering of BSR thresholds 36 , indicating that obtaining the stimulatory effects of nicotine on brain reward circuits, while avoiding its negative effects, determines the amounts of nicotine consumed by rats. We found that low doses of nicotine (0.125-0.25 mg kg 21 ; free base; injected subcutaneously) lowered BSR thresholds by a similar magnitude in the Lenti-Control and Lenti-a5-shRNA rats (Fig. 3b) . However, as the dose of nicotine was increased (1-1.5 mg kg 21 ; free base; injected subcutaneously), BSR thresholds were raised above baseline in Lenti-Control rats, but continued to be lowered below baseline levels in Lenti-a5-shRNA rats (Fig. 3b ). These data demonstrate that the stimulatory effects of nicotine on brain reward systems, which probably provide a crucial source of reinforcement that maintains the tobacco smoking habit 38 , are unaltered by deficits in a5* nAChRs in the habenulo-interpeduncular pathway. Instead, the inhibitory effects of higher nicotine doses on the activity of reward circuitries, which probably determine the amounts of nicotine that can be consumed, are greatly attenuated by knockdown of a5* nAChRs in this pathway.
Habenular a5* nAChRs regulate IPN activation
The earlier 86 Rb 1 efflux data indicate that a5 subunits transcribed in the MHb are incorporated into presynaptic a5* nAChRs in the IPN where they may regulate neurotransmitter release. Acetylcholine and glutamate are the major neurotransmitters produced by MHb neurons innervating the IPN 39 , and presynaptic a5* nAChRs are thought to regulate glutamate but not acetylcholine release in the IPN 29, 40, 41 Interestingly, glutamatergic transmission at the habenulointerpeduncular synapse is increased in response to the nicotine concentrations probably achieved in the brains of smokers 42 . Therefore, we proposed that deficient a5* nAChR signalling in the habenulointerpeduncular tract may decrease nicotine-evoked glutamatergic transmission in the IPN and thereby attenuate a negative motivational signal that limits its intake. Consistent with this hypothesis, an aversive higher dose of nicotine (1.5 mg kg 21 ) 43 , but not a rewarding lower dose (0.5 mg kg 21 ) 43 , robustly activated the IPN in wild-type mice, reflected in increased Fos immunoreactivity (Fig. 4a, b) . This effect of the high nicotine dose was almost completely abolished in knockout mice. Wild-type and a5 knockout mice showed similar Fos immunoreactivity in the ventromedial hypothalamus ( Supplementary Fig. 12 ), a region in which Fos induction is highly stress responsive 44 , indicating that altered stress responses in knockout mice did not account for this effect. Nicotine-induced increases in Fos immunoreactivity in the VTA, which controls the reinforcing effects of nicotine, were similar in wild-type and a5 knockout mice (Supplementary Fig. 13 ). Nevertheless, there was a non-statistically significant trend towards lower VTA Fos immunoreactivity in the knockout mice in response to the high nicotine dose. Considering that the VTA can also regulate aversive responses to nicotine 45 , it is possible that a5* nAChRs in the VTA may differentially regulate activation of this structure in response to aversive but not rewarding doses of nicotine. Taken together, these findings are consistent with our behavioural data in which the reinforcing effects of nicotine, probably involving VTA activation, are substantially conserved in the knockout mice. However, 
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recruitment of an aversive/satiety pathway by nicotine overconsumption, involving habenular-driven activation of IPN, is diminished in animals with deficient a5* nAChR signalling.
Habenulo-interpeduncular activity limits nicotine intake
Next we examined the effects of reversible inactivation of the habenulointerpeduncular tract on nicotine self-administration behaviour in rats, accomplished by direct microinjection of lidocaine into targeted brain sites. Lidocaine-induced inactivation of the IPN increased responding for nicotine (0.03 mg kg 21 per infusion) ( Fig. 5a and Supplementary  Fig. 14) , further supporting a role for nicotine-induced activation of the IPN in restricting nicotine intake. Conversely, inactivation of the VTA profoundly decreased nicotine intake (0.03 mg kg 21 per infusion) ( Supplementary Figs 15 and 16) . Inactivation of the MHb increased nicotine intake similarly to IPN inactivation (Fig. 5b ), but this effect was only detected when rats self-administered a higher (0.12 mg kg 21 per infusion) unit dose of nicotine ( Supplementary Figs 17 and 18 ). This effect is consistent with habenular-mediated activation of the IPN preferentially occurring when higher nicotine doses are consumed. Next we investigated the role of glutamate-mediated transmission in these brain sites in regulating nicotine intake. Microinjection of the competitive NMDA (N-methy-D-aspartate) glutamate receptor antagonist LY235959 (ref. 46 ) into the IPN dose-dependently increased nicotine self-administration (Fig. 5c ). LY235959 infused into the MHb also increased nicotine intake at the higher unit dose of nicotine, whereas infusion into the VTA decreased nicotine intake (Fig, 5d and Supplementary Fig. 16 ). Taken together, these data support a conceptual framework in which high levels of nicotine intake stimulate the habenulo-interpeduncular tract through a5* nAChRs and thereby enhance NMDA-receptor-mediated glutamatergic transmission in the IPN. This nicotine-induced enhancement of IPN activity relays an inhibitory motivational signal that limits further drug intake. Deficient a5* nAChR signalling diminishes the magnitude of this inhibitory motivational signal, permitting larger amounts of nicotine to be consumed ( Supplementary Fig. 19 ).
Our findings reveal the habenulo-interpeduncular pathway as a key neurocircuit controlling nicotine intake. This circuit acts in a manner opposite to the mesoaccumbens 'positive reward' pathway and instead transmits an inhibitory motivational signal that limits nicotine intake. There are reciprocal projections between the MHb and portions of the caudomedial VTA (interfascicular nucleus), with the VTA and IPN projecting to many common brain areas including the dorsal tegmental nucleus, raphe nuclei and dorsomedial nucleus of thalamus. Hence, it will be important to determine if direct cross-talk between VTA and IPN, or integration of reward-related information from these structures at downstream brain sites 47 , is responsible for regulating the motivational salience of nicotine and coordinating behavioural output. Our data indicate that individuals carrying risk alleles for tobacco dependence resulting in deficient a5* nAChR function are relatively insensitive to inhibitory effects of nicotine on reward pathways, consequently extending the range of nicotine doses that have net stimulatory effects on reward systems. Such a scenario is likely to be most important in the acquisition of the tobacco habit in which experiencing a negative effect of nicotine on reward pathways may decrease the likelihood of repeatedly engaging in smoking behaviour 48 . As such, these findings have important implications for understanding the high incidence of lung cancer and COPD in individuals carrying CHRNA5 risk alleles, indicating that far higher levels of nicotine can be tolerated ). Genotype, F (1,24) 5 13.50, P , 0.01; drug, F (2,24) 5 21.13, P , 0.0001; interaction, F (2,24) 5 8.64, P , 0.01. ***P , 0.001 compared with saline treatment; ****P , 0.001 compared with knockout mice at the same nicotine dose. 6 s.e.m.) number of nicotine infusions earned. a, Lidocaine infused into the IPN increased nicotine intake in rats; **P , 0.01. b, Lidocaine into the MHb increased nicotine intake in rats self-administering a high unit dose (0.12 mg kg 21 per infusion); *P , 0.05. c, LY235959 infused into the IPN increased nicotine intake in rats (n 5 9). F (3,24) 5 6.08, P , 0.01. *P , 0.05 and **P , 0.01 compared to control. d, LY235959 (10 ng per side) into the MHb increased nicotine intake in rats responding for a high unit dose (0.12 mg kg 21 per infusion; n 5 5); *P , 0.05.
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in these individuals, probably resulting in greater exposure to carcinogens contained in tobacco smoke. We have established a new framework for understanding the motivational drives that control nicotine intake. These findings are a key advance in our understanding of brain systems that regulate vulnerability to tobacco addiction, and reveal the importance of a5* nAChRs as targets for the development of novel smoking cessation therapeutics.
METHODS SUMMARY
Mice with null mutation in the a5 nAChR subunit gene and their wild-type littermates, or male Wistar rats (Charles River Laboratories), were surgically prepared with silastic catheters in the jugular vein and trained to respond on an 'active' lever for food pellets under a fixed ratio 5 time-out 20 s (FR5TO20) schedule of reinforcement. Mice and rats then responded for nicotine infusions on the FR5TO20 reinforcement schedule during 1-h daily testing sessions. Nicotine hydrogen tartrate salt was dissolved in sterile saline solution (0.9% w/v). Each nicotine reward earned resulted in the delivery of a nicotine infusion (0.033-ml injection volume delivered over 3 s in mice; 0.1 ml delivered over 1 s in rats) and initiated a 20-s time-out period signalled by a light cue located above the active lever during which responding on the lever was without consequence.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS

Animals.
Male and female mice with null mutations of the a5 nAChR subunit gene Chrna5 (a5 knockout) and their wild-type littermates were bred in our animal facilities. Brain structure and baseline behavioural measures were determined between the knock-out mice and wild-type littermates 49 . The mutant mice had been bred for more than ten generations onto a C57BL6 background. Breeding was conducted by mating heterozygous pairs. All mice were housed in cages of 1-3 and were at least 6 weeks of age at the beginning of each experiment. Male Wistar rats weighing 275-300 g were purchased from Charles River Laboratories and housed 1-2 per cage. Mice and rats were maintained in an environmentally controlled vivarium on a 12 h:12 h reversed light:dark cycle, and food and water were provided ad libitum until behavioural training commenced. During self-administration procedures, mice and rats were food restricted to 85-90% of their free-feeding body weight, but water was maintained without restriction. All procedures were conducted in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute, Florida. Genotyping. Around 21 days of age, mouse pups were weaned and their tails were clipped for genetic analysis. DNA was extracted with a tissue DNA extraction kit purchased from Biomiga. Primers for the a5 wild-type and mutant genes were: a5 wild-type forward, 59-CACTGTCACTTGGACGCAGCC-39; a5 wild-type reverse, 59-GTTCCCCTTGCTCCCCATTGC-39; Neo-1, 59-CTTTTTGTCAAG ACCGACCTGTCCG-39; and Neo-2, 59-CTCGATGCGATGTTTCGCTTGG TG-39. Samples were processed for genetic amplification with PCR and subsequently run on a 1% agarose gel with ethidium bromide. The band for the a5 wildtype gene was at 190 bp, and the a5 mutant gene was at 290 bp. Drugs. For self-administration experiments in mice and rats, (2)-nicotine hydrogen tartrate salt (Sigma) was dissolved in 0.9% sterile saline. All doses of nicotine refer to the free-base form. The NMDA antagonist LY235959 (Tocris) or lidocaine (2%; Sigma) was microinjected at a volume of 0.5 ml for over 1 min, and the injector remained in place for an additional 2 min to allow for diffusion. The pH of solutions was adjusted to ,7.4. Surgery. Mice and rats were anaesthetized with an isoflurane (1-3%)/oxygen vapour mixture and prepared with intravenous catheters. Briefly, the catheters consisted of a 6 cm (mice) or 12 cm (rats) length of silastic tubing fitted to guide cannula (Plastics One) bent at a curved right angle and encased in dental acrylic. The catheter tubing was passed subcutaneously from the animal's back to the right jugular vein, and a 1-cm (mice) or 2.5-cm (rats) length of the catheter tip was inserted into the vein and tied with surgical silk suture. Catheters were flushed daily with physiological sterile saline solution (0.9% w/v) containing heparin (10-60 USP units ml
21
). Catheter integrity was tested with the ultra short-acting barbiturate anaesthetic Brevital (methohexital sodium; Eli Lilly). Intravenous self-administration. Mice and rats were mildly food restricted to 85-90% of their free-feeding body weight and trained to press a lever in an operant chamber (Med Associates) for food pellets (20 mg pellets for mice; 45 mg food pellets for rats; TestDiet) under a fixed-ratio 5 time out 20 s (FR5TO20) schedule of reinforcement before catheter implantation. Once stable responding was achieved (.30 pellets per session in mice; .90 pellets per session in rats), subjects were catheterized as described earlier. The animals were allowed at least 48 h to recover from surgery, then permitted to respond for food reinforcement again under the FR5TO20 schedule. Once food responding criteria were re-established, subjects were permitted to acquire intravenous nicotine selfadministration by autoshaping during 1-h daily sessions, 7 days per week. Nicotine was delivered through the tubing into the intravenous catheter by a Razel syringe pump (Med Associates). Each nicotine self-administration session was performed using two retractable levers (one active, one inactive) that extend 1 cm into the chamber. Completion of the response criteria on the active lever resulted in the delivery of an intravenous nicotine infusion (0.03 ml infusion volume for mice; 0.1 ml for rats). Responses on the inactive lever were recorded but had no scheduled consequences. For dose-response studies (fixed and progressive ratio schedules), animals were presented with each dose of nicotine for at least 5 days (mice) or 3 days (rats); the mean intake over the last 3 (mice) or 2 (rats) sessions for each dose was calculated and used for statistical analysis. In between each dose, subjects were placed back on the training dose for at least 2 days or until their intake returned to baseline levels before being tested on the next dose. Surgical procedures for microinjections and electrode placement. Animals were anaesthetized as described earlier and positioned in a stereotaxic frame (Kopf Instruments). Unless otherwise noted, the incisor bar was set to the 'flat-skull' position. To test the efficacy of the re-expressing and knockdown viruses in vivo, bilateral injections were made into the hippocampus of mice or rats, respectively. This area was chosen based on the constitutive expression of the a5 nAChR subunit mRNA in wild-type animals. In mice, six bilateral injections (1 ml each at a flow rate of 1 ml per min) were made at the following coordinates: anterior-posterior (AP), 21.7 mm from bregma; medial-lateral (ML), 60.75 mm from midline; dorsal-ventral (DV), 22.05 mm, 21.80 mm and 21.35 mm from brain surface 50 . Virus injections into mouse medial habenula were aimed at the following coordinates: AP, 21.94 mm from bregma; ML, 61.06 mm from midline; DV, 22.37 from dura. In rats, the six hippocampal injections (three 2-ml injections per side at a flow rate of 1 ml per min) were made at the following coordinates: AP, 23.3 mm from bregma; ML,61.1 mm from midline; DV, 23.6 mm, 23.0 mm and 22.4 mm from brain surface 51 . For habenular injections in mice, the needle was angled 20u towards midline, and bilateral injections (0.375 ml each) were administered at a rate of 0.375 ml per min. For habenular injections in rats, the lentivirus was injected bilaterally based on previously published coordinates 52 . The incisor bar was set to 5 mm above plane, and the injector needle was at a 10u angle towards midline (AP: 22.2 mm from bregma; ML: 6 1.5 mm from midline; DV: 24.9 mm from brain surface). The bilateral injections (1 ml each) were administered at a rate of 1 ml per min. For all of the injections, the injector needle was left in place for a minimum of 2 min after injection. For IPN and VTA microinjections in rats, guide cannulae (Plastics One) were implanted as follows: IPN (flat skull; 10u angle towards midline; AP, 26.72 mm from bregma; ML, 61.6 mm from midline; DV, 26.5 mm from brain surface) or VTA (bilateral; flat skull; 6u angle towards midline; AP, 25.4 mm from bregma; ML, 61.3 mm from midline; DV, 27.0 mm from skull) 51 . The MHb guide cannula coordinates were the same as for the lentiviral injections, except with DV at 22.9 mm from brain surface. For all of the cannulae, injector needles extended 2 mm below the tip of the cannula for placement into the brain region. For the intracranial self-stimulation electrode, a stainless steel bipolar electrode (Plastics One) was implanted into the lateral hypothalamus (AP, 20.5 mm from bregma; ML, 61.7 mm from midline; DV, 28.3 mm from brain surface) 51 . BSR behavioural procedure. Rats were trained to respond according to a modification of the discrete-trial current-threshold BSR procedure of Kornetsky and Esposito 53, 54 in an operant box equipped with a wheel manipulandum and intracranial self-stimulation stimulator (Med Associates). Briefly, a trial was initiated by the delivery of a non-contingent electrical stimulus. This electrical reinforcer had a duration of 500 ms and consisted of 0.1-ms rectangular cathodal pulses that were delivered at a frequency of 50-100 Hz. The frequency of the stimulation was selected for individual rats so that threshold elevation and lowering may be detected, and this frequency was held constant throughout the experiment. A one-quarter turn of the wheel manipulandum within 7.5 s of the delivery of the non-contingent stimulation resulted in the delivery of an electrical stimulus identical in all parameters to the non-contingent stimulus that initiated the trial. After a variable inter-trial interval (7.5-12.5 s, mean of 10 s), another trial was initiated with the delivery of a non-contingent electrical stimulus. Failure to respond to the non-contingent stimulus within 7.5 s resulted in the onset of the inter-trial interval. Responding during the inter-trial interval delayed the onset of the next trial by 12.5 s. In each testing session, current levels were varied in alternating descending (32) and ascending (32) series in 5-mA steps. A set of five trials was presented for each current intensity. The threshold for each series is defined as the midpoint between two consecutive current intensities that yield 'positive scores' (animals respond for at least three of the five trials) and two consecutive current intensities that yield 'negative scores' (animals do not respond for three or more of the five trials). The overall threshold for the session is defined as the mean of the thresholds for the four individual series. Threshold data are presented as per cent of baseline values due to inter-subject variability in baseline rates. Generation of lentivirus. For a5 subunit re-expression studies, the mouse a5 nAChR subunit gene, Chrna5, was cloned into the pCDF1 lentivirus expression vector containing copGFP (GFP cloned from copepod Pontellina plumata) from Systems Biosciences. For a5 subunit knockdown studies, two different shRNAs directed against the rat Chrna5 gene were designed using the Genscript online construct builder (see Supplementary Figures for shRNA sequence) . The shRNAs were cloned into the pRNAT-U6.2/Lenti construct containing GFP (GenScript). Control vectors were identical to the expression constructs, but without the gene insert. Generation of lentivirus. To generate lentivirus supernatant, HEK 293FT packaging cells (3.75 3 10 6 293TN cells per 10-cm plate) were transfected with the vectors, along with the pPACKF1TM Lentiviral Packaging Kit using lipofectamine reagent and plus reagent (Invitrogen) according to the manufacturer's instructions. Medium containing virus particles (,10 ml) was harvested 48-60 h after transfection by centrifugation at 76,755g at room temperature (22 uC) for 5 min to pellet cell debris and filtered through 0.45 mm PVDF (polyvinylidene difluoride) filters (Millex-HV). To concentrate the viral supernatant for intrastriatal administration, supernatants were centrifuged at 32,000g for 90 min at RESEARCH ARTICLE
